New hope for men battling prostate Cancer's return
NCT ID NCT02203695
Summary
This study tested if adding a newer hormone therapy drug called enzalutamide to standard radiation treatment could better control prostate cancer that returns after surgery. It involved 86 men whose cancer had come back, as shown by a rising PSA blood test, but had not spread elsewhere. The goal was to see if this combination could keep the cancer in check longer than radiation alone, with fewer side effects than older treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF THE PROSTATE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Indiana University
Lafayette, Indiana, 47904, United States
-
Karmanos Cancer Center
Detroit, Michigan, 48201, United States
-
Oregon Health Sciences University
Portland, Oregon, 97239, United States
-
Sibley Memorial Hospital
Washington D.C., District of Columbia, 20016, United States
-
Suburban Hospital
Bethesda, Maryland, 20814, United States
-
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21287, United States
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
-
University of Michigan Health System
Ann Arbor, Michigan, 48109, United States
-
University of Utah - Huntsman Cancer Center
Salt Lake City, Utah, 84112, United States
Conditions
Explore the condition pages connected to this study.